The FDA Approves Novocure's New Head Flexible Electrode Transducer Arrays For Use With Optune Gio For Adult Patients With Glioblastoma Multiforme, Novocure Plans To Convert Optune Gio Users In The U.S. To The New HFE Arrays Through The First Half Of...
The FDA Approves Novocure's New Head Flexible Electrode Transducer Arrays For Use With Optune Gio For Adult Patients With Glioblastoma Multiforme, Novocure Plans To Convert Optune Gio Users In The U.S. To The New HFE Arrays Through The First Half Of...
美国食品药品监督管理局批准novocure的新型头部柔性电极换能器阵列用于与Optune Gio结合治疗患有多形性胶质母细胞瘤的成年人，novocure计划在今年上半年将美国的Optune Gio用户转换为新的HFE阵列。
The FDA Approves Novocure's New Head Flexible Electrode Transducer Arrays For Use With Optune Gio For Adult Patients With Glioblastoma Multiforme, Novocure Plans To Convert Optune Gio Users In The U.S. To The New HFE Arrays Through The First Half Of 2025 Through A Controlled Transition Plan
美国食品药品管理局批准Novocure的新型头部柔性电极探头阵列与Optune Gio一起用于成年多形胶质母细胞瘤患者，Novocure计划通过受控过渡计划，在2025年上半年之前将美国的Optune Gio用户转换为新的HFE阵列
Optune Gio is a wearable, portable device that produces alternating electric fields known as Tumor Treating Fields (TTFields), which are delivered through non-invasive, wearable arrays. TTFields exert physical forces on the electrically charged components of dividing cancer cells, which disrupt the rapid cell division exhibited by cancer cells.
Optune Gio是一种可穿戴的便携式设备，可产生称为肿瘤治疗场（TTFields）的交替电场，通过非侵入性的可穿戴阵列传输。TTFields 对分裂癌细胞的带电成分施加物理力，从而破坏癌细胞表现出的快速细胞分裂。
The new HFE arrays utilize a flexible polymer material in place of the ceramic discs used in the current Optune Gio arrays, making them one-third lighter and 50% thinner.
新的HFE阵列使用柔性聚合物材料代替了当前Optune Gio阵列中使用的陶瓷圆盘，使其重量减轻了三分之一，薄了50％。
资讯热榜
更新时间